In Parkinson's disease (PD), rating scales are used to assess the degree of disease-related disability and to titrate long-term treatment to each phase of the disease. Recognition of non-motor symptoms required modification of existing widely used scales to integrate non-motor elements. In addition, new scales have been developed for the assessment of non-motor symptoms. In this article, assessment of PD patients will be discussed, particularly for non-motor symptoms such as pain and fatigue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1353-8020(11)70070-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.
J Neurol
January 2025
Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Background And Objective: Non-motor symptoms frequently develop throughout the disease course of Parkinson's disease (PD), and pose affected individuals at risk of complications, more rapid disease progression and poorer quality of life. Addressing such symptom burden, the 2023 revised "Parkinson's disease" guideline of the German Society of Neurology aimed at providing evidence-based recommendations for managing PD non-motor symptoms, including autonomic failure, pain and sleep disturbances.
Methods: Key PICO (Patient, Intervention, Comparison, Outcome) questions were formulated by the steering committee and refined by the assigned authors.
P300 Event-Related Potential: A Surrogate Marker of Cognitive Dysfunction in Parkinson's Disease Patients with Psychosis.
Ann Indian Acad Neurol
January 2025
Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.
Background And Objectives: Psychosis is one of the major neuropsychiatric non-motor symptoms of Parkinson's disease (PD). Prolonged latency and decreased amplitude of the P300 event-related potential (ERP) is a potential neurophysiologic biomarker of deeper neurocognitive deficits in PD. We aimed to characterize electroencephalogram (EEG)/ERP parameters in PD patients with and without psychosis (PDP and PDNP, respectively), and to determine if such measures could act as endophenotypes for PD-associated psychosis (PDP).
View Article and Find Full Text PDFPre-DBS modified Tremor/Postural instability and gait difficulty score ratio as indicator of short-term outcome of subthalamic nucleus DBS in Parkinson's disease.
J Mov Disord
January 2025
Parkinson and Movement Disorder Centre, Centre of Excellence in Neurosciences, Aster Medcity, Kochi, India.
Purpose: The outcomes of motor and non-motor features of Parkinson's disease (PD) following DBS vary among its subtypes. We tested whether pre-operative motor subtyping using the modified Tremor/PIGD ratio, could indicate the short-term motor, non-motor and quality of life (QOL) outcomes of STN-DBS.
Method: In this prospective study, 39 consecutive STN-DBS cases were assessed in Drug-OFF state before surgery and subtyped using the ratio of tremor and PIGD scores (T/P ratio).
Secondary analysis reveals gut microbiota differences in patients with Parkinson's disease and/or cognitive impairment.
Microbiome Res Rep
August 2024
Department of neurology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200, Shandong, China.
Parkinson's disease (PD) is a neurodegenerative disorder, and the main clinical characteristics are bradykinesia and muscle stiffness. Cognitive impairment (CI) is a prevalent non-motor manifestation observed in individuals with PD. According to disease severity, it can be divided into PD with mild cognitive impairment (MCI) and PD dementia.
View Article and Find Full Text PDFThe Use of Cannabis-Based Medicine in Selected Neurological Disorders.
Curr Top Behav Neurosci
December 2024
Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
Cannabis-based medicine (CBM) is used in a wide variety of different neurological disorders. While the use of CBM in the treatment of pain, AIDS wasting, loss of appetite, and spasticity is well established, CBM application in movement disorders and neurodegenerative disorders is still an emerging topic. The purpose of this chapter is to summarize current evidence behind the use of CBM in selected neurological diseases, mainly movement and neurodegenerative disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!